Successful treatment of Acute Fulminant Liver Failure due to Hepatitis B virus with Entecavir in patients with contra-indications to liver transplant

Mukul Bhattarai, Pardeep Bansal, Michael Komar, Robert E. Smith, Hitekshya Nepal

Geisinger Health System, Danville, PA, United States.

ABSTRACT

There are no randomized clinical trials on efficacy of Entecavir in Fulminant Hepatic Failure (FHF) due to Hepatitis B Virus (HBV). Definitive treatment of FHF remains Liver Transplant. However, availability of cadaveric donor organs is limited, and many of the patients with FHF may not be candidates for Liver Transplantation. There are only few case reports on beneficial effects of Entecavir in FHF due to HBV. We present 2 cases of FHF due to HBV. Both patients had severe liver cell damage among which one was immunocompromised. Transaminases were elevated up to 200 times the normal. Both were not transplant candidates, and were successfully treated with Entecavir resulting in significant clinical and transaminases improvement within 7 days of starting Entecavir.

INTRODUCTION

Acute fulminant liver failure refers to the rapid deterioration of liver synthetic function and encephalopathy typically within 8 weeks of the onset of symptoms in a patient with a previously healthy liver. Hepatitis B virus (HBV) is probably the most common viral cause of FHF. Fulminant liver failure due to hepatitis B viral (HBV) infection can have mortality of 60 to 90%. The only therapy proven to improve patient outcome in FHF is orthotopic liver transplantation, which is associated with one-year survival rates of greater than 80 percent. Prior to transplantation, most series suggested less than 15% survival. However, in this era of liver transplantation, the availability of cadaveric donor organs is limited. Even when available it would be contraindicated in different grounds. Moreover, there are many regions in the world where transplant facilities are unavailable or unaffordable resulting in high mortality of FHF secondary to HBV. Therefore in such scenario Entecavir therapy seems to be beneficial shown in few case reports including ours. We present 2 cases of FHF due to HBV, who were not transplant candidates, and were successfully treated with Entecavir and supportive care in our transplant center.

Case 1: A 45 year old female was transferred to our medical center with FHF from HBV. She presented with jaundice and altered mental status. Liver Function Tests (LFT’s) were remarkable for ALT 6420, AST 6470, total bilirubin 9.65, INR 5.5 (Table-1 and Graph 1). Her ammonia level at presentation was elevated to 189 umol/L, which went up to 201 umol/L next day. Non contrast CT of head showed mild cerebral edema without any signs of hemorrhage.

She had a history of intravenous drug abuse and her toxicology screen was positive for opium and cocaine. HBV DNA was 1432 copies/mL. She was deemed not to be a liver transplant candidate because of significant socio-psychiatric issues including drug abuse and depression requiring hospitalizations in past. She was admitted in intensive care unit, was intubated and started on 3% hypertonic normal saline with intracranial pressure monitoring. Liver biopsy revealed Acute Fulminant Hepatitis with necrosis of 50% of the hepatic parenchyma (Figure 1 and 2). She was started on Entecavir 1 mg daily. From day 4 on treatment, she started showing slight improvement in her mental status and LFT’s started to improve (Table 1 and Graph 1). She was eventually extubated and was discharged home on Entecavir on day 11. In hepatology clinic follow up in 2 weeks, she was almost completely back to her baseline activity with mildly elevated ALT and AST and her Entecavir was stopped.

*Corresponding author
Mukul Bhattarai
100 N Academy Ave, Danville
Pennsylvania, USA 17822
Email: drmukulbhattarai@gmail.com
Case 2: A 84 year old female with Large B cell Lymphoma who was started on Rituxan about 4 weeks ago, presented with jaundice reactivation of chronic HBV infection. LFT’s were remarkable for ALT 4516, AST 3007, total bilirubin 16.3, INR 1.46. HBV PCR was 2547607 IU/ml. She started developing confusion on the day after admission. CT head did not show any evidence of an acute intracranial process. She was not a liver transplant candidate because of her advanced age and Lymphoma. She was started on Entecavir 1mg daily with improving her LFTs as shown in Table 2 and Graph 2. She received Entecavir of total seven days.

Entecavir was approved in 2006 for the treatment of chronic hepatitis B and offers the advantage of a higher resistance barrier than lamivudine.13

As per AASLD 2011 practice guidelines, the nucleoside analog lamivudine (and possibly other nucleos(t)ide analogues), used widely in the treatment of chronic hepatitis B, may be considered in patients with acute hepatitis B, although evidence of efficacy is equivocal.10-11 In another case series on two patients with severe acute hepatitis B were immediately started treatment with lamivudine in view of the prolonged prothrombin time.16 But there was no evidence of adequate recovery of liver function. Improvement followed after switching the antiviral therapy to Entecavir or to an add-on with...
Adeovir demonstrating that Entecavir seem to be efficacious in acute hepatitis B therapy when lamivudine has failed. There is very limited experience with the use of newer nucleotide analogue like Entecavir and Tenofovir in the treatment of FHF and HBV reactivation. Based on these case reports and case series, we tried Entecavir in our two patients, who were not transplant candidate, with successful outcome.

The reactivation of HBV is common with immunosuppressive therapy if they are not on anti-HBV prophylaxis as in our Case 2. All patients prior to initiation of immunosuppressive therapy should be checked for HBV. Patients found to be positive for HBsAg who are to begin immunosuppressive therapy should be treated prophylactically with a nucleos(t)ide analog, and that treatment should be continued for six months after completion of immunosuppressive therapy. In the case series published by Brost et al, one patient on Lamivudine prophylaxis had reactivation of HBV infection and was successfully treated with Entecavir. There is a single case report from Japan of drug-induced liver injury caused by Entecavir for treatment of hepatitis B virus reactivation during rituximab/cyclophosphamide/ doxorubicin/vincristine/prednisolone (RCHOP) in a patient with non-Hodgkin lymphoma. Other side effect which is reported with Entecavir in a case series of 16 patients is Lactic acidosis. In this case series 5 out of 16 patients treated with Entecavir developed lactic acidosis. All patients who developed lactic acidosis had highly impaired liver function (Model for End-Stage Liver Disease [MELD] score > or = 20). Lactic acidosis (lactate 26-200 mg/dL, pH 7.02-7.40, base excess -5 mmol/L to -18 mmol/L) occurred between 4 and 240 days after treatment initiation with Entecavir. Lactic acidosis was lethal in one patient but resolved in the other cases after termination/interruption of Entecavir treatment. Our both patient were monitored for lactic acidosis and both patients had lactic acid level of less than 4 mmol/L during the treatment.

**CONCLUSION:**

Our cases suggest that a prompt and timely initiation of antiviral therapy nucleoside inhibitor such as Entecavir in patients with FHF from HBV seems to be beneficial. Design of a multicenter double blind randomized trial to compare the efficacy of lamivudine and newer antiviral agents (like Entecavir or Tenofovir) in FHF from HBV would be helpful. However, such a trial is difficult to perform as these cases are not frequent and are associated with high mortality rate. In the meantime, Entecavir appears promising as it is well tolerated in patients with FHF. It has potent antiviral activity with low rate of drug resistance and should be considered in patients with FHF from HBV who are not transplant candidates. These rare cases would be extremely useful to help physicians making the decision to consider Entecavir in acute fulminant hepatitis who is not a transplant candidate or where such transplant facilities are not available.

**REFERENCES**

1. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012 Apr;32(4):544-53.


